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Abstract: Polycystic ovary syndrome (PCOS), one of the most frequent endocrine diseases, 
affects approximately 5%–10% of women of childbearing age and constitutes the most common 
cause of female sterility regardless of the need or not for treatment, a change in lifestyle is 
essential for the treatment to work and ovulation to be restored. Obesity is the principal reason 
for modifying lifestyle since its reduction improves ovulation and the capacity for pregnancy 
and lowers the risk of miscarriage and later complications that may occur during pregnancy 
(gestational diabetes, pre-eclampsia, etc). When lifestyle modification is not sufficient, the 
first step in ovulation induction is clomiphene citrate. The second-step recommendation is 
either exogenous gonadotrophins or laparoscopic ovarian surgery. Recommended third-line 
treatment is in vitro fertilization. Metformin use in PCOS should be restricted to women with 
glucose intolerance.
Keywords: polycystic ovarian syndrome, clomiphene citrate, letrozole, lifestyle, pregnancy, 
obesity
Polycystic ovary syndrome (PCOS), one of the most frequent endocrine diseases, 
affects approximately 5%–10% of women of childbearing age1,2 and constitutes the 
most common cause of female sterility. This syndrome not only produces an alteration 
at reproduction level, but could also be labeled as a systemic involvement syndrome. 
Factors implicated in the low fertility in these patients include anovulation,1 increased 
risk of early miscarriage3 and late obstetric complications.4 Obesity is also a common 
finding in these patients5 and this condition appears to affect reproductive capacity.6,7
Polycystic ovary syndrome is an ovarian dysfunction. The main characteristics 
of the syndrome are hyperandrogenism and polycystic ovary morphology. Clinical 
manifestations include menstrual disorders, signs of hyperandrogenism and obesity. 
PCOS is associated with an increased risk of type 2 diabetes mellitus owing to the 
appearance of insulin resistance.
The diagnostic criteria of the syndrome were revised by the Rotterdam ESHRE/
ASRM-Sponsored PCOS Consensus Workshop Group in 2003 where the following 
criteria were established: oligoamenorrhea, clinical and biochemical signs of hyperan-
drogenism, and echographically confirmed polycystic ovary. Two of the three criteria 
are required for diagnosis. The advantages and disadvantages of these criteria, and 
particularly the different phenotypes and wide spectrum of the syndrome, have been 
discussed in later publications.8Therapeutics and Clinical Risk Management 2009:5 354
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Although progress has been made over the years in the 
unanimous acceptance of the diagnostic criteria worldwide, 
unification of criteria regarding treatment when children are 
desired remain to be established. Various publications9,10 
have proposed a global update on lifestyle, medical 
ovulation-induced treatments, insulin-sensitizing agents, 
surgical treatments, or the application of assisted reproduc-
tion techniques.11 All of these were recently revisited by the 
Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus 
Workshop Group’s report on consensus in infertility treat-
ment related to PCOS.
Changes in lifestyle
Changes in the lifestyle of these patients must be the first 
recommendation, particularly when their body mass index 
(BMI) exceeds 28. It is well established that obesity is 
associated with ovulation,12 miscarriage,13 or late preg-
nancy complications (such as pre-eclampsia and gestational 
diabetes).14 Obesity is common in PCOS and is related to 
lack of or delayed response to different treatments such as 
clomiphene citrate (CC),15 gonadotrophins,12,16 and surgical 
treatment of diathermy via laparoscopy.17
Weight loss appears to reverse the hormone disorders 
associated with PCOS (raised plasma sex hormone-binding 
globulin (SHBG) concentrations and lowered insulin and 
androgen levels) and thus improve ovulation11 and pregnancy 
rates.18 A 5%–10% loss of initial weight could suffice to 
re-establish ovarian function. The treatment of obesity 
includes modifications in lifestyle (diet and exercise) and 
medical and surgical treatment.
All these treatments must be performed during the 
pre-conception period and not jointly with reproduction 
therapies.
Diet
It is well known that a restricted calorie intake is necessary 
to lose weight. In patients without PCOS, low carbohydrate 
diets suffice to reduce weight, which appears to be particu-
larly important in patients with PCOS and associated insulin 
resistance.19 Diets recommended for obese PCOS patients 
are low in calories with a reduced carbohydrate intake 
and any form of these diet can produce the 5%–10% loss 
necessary to re-establish ovarian function in these patients. 
Only two controlled, randomized studies compared the 
effect of different diets in patients with PCOS.18,19 Those 
studies showed that different diet patterns failed to produce 
significant changes in weight loss or reproduction results.18 
In 2005, Reaven suggested that low-fat diets produce a 
decrease in hyperinsulinemia, which improves metabolic 
effects.19
Exercise
Several studies have attempted to establish the role of 
exercise20 in the treatment of obese PCOS patients. None 
found significant differences when different diets, associ-
ated or not with exercise, were compared, although a longer 
weight loss maintenance time did appear to be associated 
in these patients.21 An increase in physical activity is recom-
mended for PCOS patients, although they often present 
limitations.18
Clomiphene citrate
Clomiphene citrate is an estrogen antagonist that produces 
an increase in circulating follicle-stimulating hormone (FSH) 
concentrations by negative feedback blockage, thereby 
inducing follicular growth in patients with PCOS and 
ovulation. CC constitutes one of the first-line treatments for 
ovulation induction in these patients since it is economical, 
straightforward, has few adverse effects, and requires little 
monitoring.22
Treatment is started with a dose of 50 mg/day for five 
days from the 2nd to 5th days of the cycle. The daily dose 
can be increased to 150 mg/day without exceeding the US 
Food and Drug Administration (FDA) recommendations of 
750 mg/cycle,23 and six cycles can be performed.
Clomimphene citrate is indicated in patients with PCOS 
and anovulation, with normal FSH levels, but has certain 
limitations in patients with BMI  30 and advanced age. 
Legro and colleagues24 found significant differences in 
pregnancy rates in patients with BMI  30 compared with 
those with BMI  30.
Echographic cycle monitoring does not appear to ensure 
good results; therefore, in practice, some centers only monitor 
the first cycle to adjust the dose according to the patient’s 
response. CC produces ovulation in 75%–80% of PCOS 
patients,22,25 although when the gestation rate is assessed, 
it nears 22% per ovulation cycle. These differences in 
results are attributed to the antiestrogenic effects of CC.22,25 
Multiple pregnancy rates are under 10% and hyperstimula-
tion syndrome is rare.26
Combined therapy: clomiphene 
citrate and metformin
A randomized study27 found no increase in the pregnancy 
rate when CC and metformin alone or in combination were 
compared. Pregnancy and live birth rates were higher with Therapeutics and Clinical Risk Management 2009:5 355
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CC compared with metformin, with similar adverse effects. 
Other studies28–31 observed benefits when metformin was 
included, however, they did not provide data on pregnancy 
rates and appeared to be small studies. There is currently no 
study that establishes metformin as an essential treatment 
for ovulation induction in women with PCOS.
A review published in 200532 concluded that treatment 
with insulin-sensitizing agents must not be recommended 
in all patients with PCOS, but only in those who also have 
insulin resistance and obesity. However, if their use is neces-
sary, metformin is the first choice insulin-sensitizing agent 
and that with which better results have been obtained than 
with placebo. Metformin is also an alternative for patients 
who present manifest hyperandrogenism. A recent American 
review33 emphasized the use of metformin to improve 
associated disorders in PCOS patients (insulin resistance, 
type 2 diabetes, dyslipidemia, and cardiovascular alterations). 
Metformin is not as effective as CC for ovulation induction; 
however, their combined use is better than with placebo. 
The usefulness of metformin in reducing miscarriages and 
improving pregnancy outcome is also in doubt; for this 
reason, the dosage during pregnancy is not clear. The authors 
of the review concluded that metformin regains its useful-
ness in all these situations when PCOS patients present the 
aforementioned associated disorders.
Insulin sensitizers
Insulin resistance affects 10%–25% of the general population. 
This finding, together with hyperinsulinemia, appears to be 
present in a significant number of PCOS patients. Some 
authors believed it would be an independent component of 
obesity,34 while others associated insulin resistance in PCOS 
only with obese patients.35
In addition to the fertility disorders caused by insulin 
resistance and hyperinsulinism in women with PCOS, an 
increased risk of developing type 2 diabetes mellitus,36–38 
dyslipidemias, and cardiovascular disease is also provoked. 
Acien and colleagues39 and Meirow and colleagues40 reported 
that approximately 10% of patients with PCOS and no 
obesity could present insulin resistance. Weight reduction 
in these patients is accompanied by an increase in insulin 
sensitivity41–44 followed by association of hyperandrogenism 
and restored ovulation,45–49 although the diet abandonment 
rate in these women owing to lack of motivation due to 
difficulty in achieving significant weight loss is high. This 
lack of adherence to diets and abandonment were the main 
reasons for using drugs to induce ovulation and achieve 
pregnancy.
Insulin-sensitizing agents, in particular metformin, are 
considered to be a first-line treatment in some regions where 
women with PCOS have a characteristic phenotype, since 
they normalize hyperandrogenism, induce ovulation, and 
protect from early pregnancy losses.50
Metformin, a hypoglycemia biguanide, is a category B 
drug (FDA recommendation). Its principal action is to lower 
glucose by inhibiting liver production without producing 
hypoglycemia in normoglycemic subjects, since it increases 
the number of receptors but not insulin secretion. Metformin 
improves glucose absorption, therefore the treatment 
improves insulin sensitivity and hyperandrogenism, increases 
SHBG concentration, lowers luteinizing hormone (LH) 
concentration and, in the liver, stimulates gluconeogenesis 
and inhibits glucogenolysis.
Metformin reduces total testosterone and raises SHBG 
levels, producing a decrease in the free testosterone index. 
It does not act on BMI51 but does appear to act on hirsutism 
and acne and induce the onset of regular cycles.52 Adverse 
effects of the drug include gastrointestinal disorders, mainly 
diarrhea, which improve when the dose is reduced or the 
drug is taken with meals. The most severe adverse effect is 
lactic acidosis.
Other insulin-sensitizing agents used are tiazolidindiones 
such as rosiglitazone and pioglitazone, which are effective 
in ovulation induction. They are category C (FDA). Their 
principal mechanism of action is to increase the capacity of 
muscle to metabolize glucose, which permits a reduction in 
insulin resistance.
One large study by Legro and colleagues reported a 
disadvantage of metformin compared with CC. The results 
did not appear to improve when metformin and CC were 
combined, except when BMI was 35. CC appeared to 
improve results compared with metformin when ovulation, 
conception, pregnancy, and live births were assessed.
Thus, from observing the different studies on the topic, 
and although some studies reported opposing results but did 
not seem to have significant scientific evidence, metformin 
would not appear to be a first-line treatment in patients with 
PCOS and the desire for children. Although metformin 
appears to be safe during pregnancy,24 interruption of the 
treatment is advised since no well-designed studies exist 
demonstrating its safety.
Gonadotrophins and GnRH analogues
The second possible line of therapy, after resistance to CC 
has been demonstrated in women with PCOS, is exog-
enous gonadotrophins. As revised by the Thessaloniki Therapeutics and Clinical Risk Management 2009:5 356
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ESHRE/ASRM-Sponsored PCOS Consensus Workshop 
Group, the mechanism of action of  gonadotrophins is to induce 
ovulation, maintain and provoke optimum follicle growth via 
the controlled administration of FSH, and achieve a follicle 
capable of being fertilized. The application of this concept 
is essential in women with PCOS since they have an excess 
of follicle production without reproductive capacity.53–55 The 
main drawbacks of gonadotrophins are that they provoke 
multiple follicle development, thereby increasing the risk 
of ovarian hyperstimulation syndrome (OHS) and multiple 
pregnancy. In order to minimize these drawbacks, anticon-
ceptives have been used during the months prior to the start of 
the stimulation cycle and, above all in women with polycystic 
ovary, combined with metformin four to six weeks before 
the cycle starts to reduce follicle recruitment and avoid cycle 
cancellation.56–58
The usual FSH dose is 150 IU/day, which is significantly 
reduced to 75–37.5 IU/daily in women with polycystic ovary 
to lower the risk of hyperstimulation syndrome, which is 
raised in patients with PCOS. A maximum of six cycles with 
gonadotrophins is recommended since no response with six 
cycles signifies resistance. Two main protocols are used 
as shown in the consensus on infertility treatment related 
to polycystic ovary syndrome: the step-up and step-down 
regimens.53
The step-up regimen starts with a minimum dose, which 
increases according to the lack of follicle response. Control 
is made by ultrasound and the regimen is modified after one 
week of no follicle growth with a 50% increase each time as 
required. The duration of treatment is usually 7–14 days.
The step-down regimen starts with the maximum recom-
mended dose, which is reduced as follicle response is 
achieved. The dose is reduced by 50% each time the regimen 
is changed.
Initially, treatment was started using the two protocols in 
the same way since with these regimens it is easier to avoid 
the main undesired effects of hyperstimulation syndrome 
and multiple pregnancies. However, recent studies have 
demonstrated greater safety for patients using the step-up 
regimen.59 The latest results with step-up regimens include 
approximately 70% ovulatory cycles, 20% pregnancies, and 
a 5.7% reduction in multiple pregnancies, and thus provide 
a therapeutic option to be considered.60
The search for improved efficacy has recently led to the 
consideration of the option of a combination of GnRH agonists 
and gonadotrophins. The use of LH may optimize follicle 
maturation and avoid anticipated spontaneous ovulation. As 
a drawback, it has been observed that high plasma LH levels 
are associated with a significant rise in lost pregnancies. At 
present, the regimen is not well established owing to the lack 
of studies confirming its usefulness and efficacy.
Monitoring is essential in gonadotrophins treatment to 
avoid the risk of hyperstimulation and multiple pregnancies. 
Cancellation criteria are not yet established. The latest studies 
state that for a cycle to be efficacious and produce a good 
result, there should not be more than two follicles 14 mm 
or no more than three or four follicles of 10 mm. In 2006, the 
ASRM advocated caution and strict control when the blood 
estradiol levels exceeded 2500 pg/ml during induction.61
Letrozole
Letrozole is a third-generation aromatase inhibitor (AI) used 
as an alternative to tamoxifen in women with breast cancer. 
It was introduced as an assisted reproduction treatment 
(ART) following the appearance of multiple adverse effects 
of CC, CC’s scant therapeutic success, and the complexity 
of gonadotrophin treatment.
Letrozole inhibits estrogen production in the hypothalamus–
pituitary axis, which implies an increase in GnRH and FSH. 
It is believed that there exists a relative decrease in aromatase 
in PCOS women, which reduces the production of follicles 
responsible for efficacious ovulation. To use this relative 
deficit, aromatase inhibitors were considered in order to 
provoke ovulation, since their selective action of blocking 
the peripheral passage of androgens to estrogens reduces the 
quantity of estrogens, thereby producing a positive feedback 
in the pituitary, increasing FSH, and optimizing ovulation. 
The advantage of letrozole is that it avoids peripheral anti-
estrogenic effects on the endometrium, while stimulating 
monofollicular growth.56,62,63
Aromatase inhibitors64 were proposed as a therapeutic 
option owing to their selectivity of action which is produced 
only at gonadal level without affecting other organs such 
as the brain, while avoiding the adverse effects produced 
by reduced estrogen in the system. Different generations of 
AI exist. For ART, the use of third-generation AI is recom-
mended owing to their greater selectivity, greater potency, 
and lesser adverse effects.65,66 Of the third-generation AI, both 
letrozole and anastrozole are available. In vitro studies have 
shown letrozole to have greater potency and better plasma 
levels than anastrozole. For this reason, the majority of ART 
are performed with letrozole.65–67
Letrozole at 2.5–5 mg is administered for five days 
and may be accompanied by FSH (at the normal doses of 
PCOS patients) and human chorionic gonadotropin (hCG; 
10,000 IU) when the follicle diameter reaches 18 mm Therapeutics and Clinical Risk Management 2009:5 357
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to program the ovulation. The half-life is now known to 
be approximately 45 hours and letrozole is completely 
eliminated at 17 days.68 A priori, the therapeutic option of 
AI would appear to be able to replace clomiphene citrate as 
a first-line treatment for patients with polycystic ovaries and 
those who fail to respond to conventional treatments.
This year saw the publication of a meta-analysis, which 
systematically reviewed all the articles on the use of letro-
zole in ART.69 This meta-analysis revealed a paucity of 
randomized studies and the difficulty in performing a 
correct statistical analysis owing to the lack of significant 
data. The authors showed with their comparison that results 
have not improved (ovulation cycle, ovulation induction, 
pregnancy) in a statistically significant manner with the use 
of letrozole.
Furthermore, recent studies showed the possibility of an 
increase in congenital heart diseases and skeletal malforma-
tions in neonates fertilized by ART using letrozole, although 
the teratogenicity is not confirmed.70 It can be seen from 
the above that scientific evidence is lacking for the use of 
letrozole as the ART of choice.53
In vitro fertilization techniques
The last possibility for achieving a full-term pregnancy 
in women with PCOS is to use in vitro reproduction tech-
niques.53 Patients with polycystic ovaries are characterized 
by anovulatory cycles that conceptually are not an indication 
for in vitro fertilization (IVF) techniques. These techniques 
are used as a last resort when treatments with CC, gonado-
trophins, and letrozole have failed.
IVF is the first choice in cases of concomitant diseases 
both in women (severe endometriosis, neural tube defect, etc) 
and men (azoospermia, male factor) that reduce the effec-
tiveness of other techniques. Several useful protocols, CC, 
gonadotrophins or AI, can be used in this type of patient, 
although the most standard protocol is long FSH-associated 
desensitization.
A meta-analysis published in 2006, which studied the 
results of conventional IVF techniques in women with PCOS, 
revealed more cycle cancellation (12.8% versus 4.1%; odds 
ratio, 0.5; 95% confidence interval [CI]: 0.2–1.0) and that 
the duration of stimulation cycles was significantly longer 
in women with PCOS (1.2 days; 95% CI: 0.9–1.5).71 There 
is evidence that the use of metformin improves viable preg-
nancy rates and reduces the incidence of ovarian hyperstimu-
lation syndrome (OHS).72
OHS is the main complication to be feared in IVF 
techniques and even more so in patients with PCOS. There is 
currently no treatment to avoid it; thus, correct monitoring of 
the treatment will prevent the onset of this syndrome and its 
severity. The success of IVF techniques is similar to that of 
patients without PCOS, which implies that PCOS does not 
intervene in embryo implantation.
Surgical techniques
The surgical techniques traditionally employed were a 
bilateral wedge resection and laparoscopy surgery of the 
ovary using a diathermy loop or laser. The former, despite 
its aggressivity, is widely used in current practice, but is 
not currently used as a therapeutic alternative in PCOS 
patients.53 The latter consists of ovarian drilling (multiple 
controlled perforation of the ovary).73 It has recently been 
reported53 that the sole indication for laparoscopy, at 
present, is in cases of resistance to CC, ie, in patients who, 
despite the treatment, do not achieve ovulatory cycles. 
Laparoscopy has also been recommended in patients with 
LH hypersecretion, those with an anatomical–functional 
problem of the pelvis, or those who reside far from a center 
where the treatment can be closely controlled. It is not a 
treatment of choice since its therapeutic effect lapses at six 
months and may thus be used only as a last resort.53,56,74,75 The 
danger implicit in these techniques is the extent of the lesion 
and repercussions on ovarian parenchyma. For this reason, 
they are not recommended as a prevention of hyperstimu-
lation (OHS).76
A further possibility for laparoscopy is to combine it with 
another ART such as bilateral salpingectomy for bilateral 
hydrosalpinx followed by an IVF technique, although this 
situation is not usual in patients with PCOS. In conclusion, 
laparoscopy as an ART would be an aggressive alternative 
and its indication would thus have to be contextualized and 
tailor-made to the patient.
Conclusions
Symptoms in women with PCOS range widely: from those 
with biochemical disorders that do not affect clinical status 
to those who fulfill all the criteria of the syndrome. For 
this reason treatment should be individualized according to 
whether or not there is a desire for children.
Regardless of the need or not for treatment, a change in 
lifestyle is essential for the treatment to work and ovulation 
to be restored. Obesity is the principal reason for modifying 
lifestyle since its reduction improves ovulation and the 
capacity for pregnancy and lowers the risk of miscarriage 
and later complications that may occur during pregnancy 
(gestational diabetes, pre-eclampsia, etc).Therapeutics and Clinical Risk Management 2009:5 358
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It has also been demonstrated that the essential step to 
achieve significant weight loss is to reduce calorie intake, 
regardless of the physical exercise that may be associated.
The next step, if there is a desire for children, is to apply 
an ovulation-inducing treatment. In women with PCOS, the 
first option is currently CC. However, despite CC being the 
first choice, many possible alternatives are being established: 
gonadotrophins, AIs, etc. The problem is a lack of scientific 
evidence showing their efficacy and possible superiority. 
Thus, more randomized clinical trials are required to demon-
strate significant differences among treatments. In summary, 
the treatment of PCOS-associated infertility consists of effi-
cacious ovulation induction to achieve homeostasis.
The choice of treatment should be contextualized and 
individualized. Treatment is started not to induce ovulation 
with hormone therapy but to prepare the best context possible 
to protect a future pregnancy. Thus, an improved lifestyle 
and above all weight loss must be emphasized. In cases of 
insulin resistance that do not improve with slimming, drugs 
such as metformin that help to regulate homeostasis and 
facilitate ovulation recovery can be used.
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